Author:
Merrill Joan T.,Buyon Jill P.
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Dey, E. UPDATE 2—La Jolla stops developing lupus drug; shares tank.
http://www.reuters.com/article/marketsNews/idUSBNG16819820090212
(2009).
2. Study of LJP 394 in lupus patients with history of renal disease (ASPEN).
http://www.clinicaltrials.gov/ct2/show/NCT00089804
(2009).
3. Furie, R. A. et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28, 257–265 (2001).
4. Alarcón-Segovia, D. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48, 442–454 (2003).
5. Cardiel, M. H. et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 58, 2470–2480 (2008).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献